GridAI Technologies (GRDX) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GridAI Technologies is the larger company by market cap ($34.2 million vs $26.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRDX | MCRB |
|---|---|---|
| Share price | $4.80 | $2.63 |
| Market cap | $34.23M | $26.42M |
| 1-day change | +16.50% | -3.31% |
| YTD return | +3.00% | — |
| 1-year return | +20.00% | — |
| 5-year return | -99.99% | — |
| EPS (TTM) | $-5.65 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.93 | $29.98 |
| 52-week low | $1.87 | $2.42 |
| Distance from 52-week high | -30.73% | -91.23% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +546.39% |
| Average volume | 104.68K | 73.43K |
| Shares outstanding | 7.13M | 10.04M |
| Employees | — | 66 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Healthcare · Biotechnology
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 66 employees
GRDX vs MCRB FAQ
Which is bigger, GridAI Technologies or Seres Therapeutics?
GridAI Technologies (GRDX) is larger, with a market capitalization of $34.23M compared with $26.42M for Seres Therapeutics (MCRB).
Are GridAI Technologies and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.